{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:09:40Z","timestamp":1773806980569,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01-CA166009"],"award-info":[{"award-number":["P01-CA166009"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>\u03b3-Secretase is a multiprotein protease that cleaves amyloid protein precursor (APP) and other type I transmembrane proteins. It has two catalytic subunits, presenilins 1 and 2 (PS1 and 2). In our previous report, we observed subtle differences in PS1- and PS2-mediated cleavages of select substrates and slightly different potencies of PS1 versus PS2 inhibition for select \u03b3-secretase inhibitors (GSIs) on various substrates. In this study, we investigated whether \u03b3-secretase modulators (GSMs) and inverse \u03b3-secretase modulators (iGSMs) modulate \u03b3-secretase processivity using multiple different substrates. We next used HEK 293T cell lines in which <jats:italic>PSEN1<\/jats:italic> or <jats:italic>PSEN2<\/jats:italic> was selectively knocked out to investigate processivity and response to GSMs and iGSMs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>For cell-free \u03b3-secretase cleavage assay, recombinant substrates were incubated with CHAPSO-solubilized CHO or HEK 293T cell membrane with GSMs or iGSMs in suitable buffer. For cell-based assay, cDNA encoding substrates were transfected into HEK 293T cells. Cells were then treated with GSMs or iGSMs, and conditioned media were collected. A\u03b2 and A\u03b2-like peptide production from cell-free and cell-based assay were measured by ELISA and mass spectrometry.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Result<\/jats:title>\n                <jats:p>These studies demonstrated that GSMs are highly selective for effects on APP, whereas iGSMs have a more promiscuous effect on many substrates. Surprisingly, iGSMs actually appear to act as like GSIs on select substrates. The data with <jats:italic>PSEN1<\/jats:italic> or <jats:italic>PSEN2<\/jats:italic> knocked out HEK 293T reveal that PS1 has higher processivity and response to GSMs than PS2, but PS2 has higher response to iGSM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Collectively, these data indicate that GSMs are likely to have limited target-based toxicity. In addition, they show that iGSMs may act as substrate-selective GSIs providing a potential new route to identify leads for substrate-selective inhibitors of certain \u03b3-secretase-mediated signaling events. With growing concerns that long-term \u03b2-secretase inhibitor is limited by target-based toxicities, such data supports continued development of GSMs as AD prophylactics.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-020-00622-5","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T16:05:07Z","timestamp":1589904307000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["\u03b3-Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse \u03b3-secretase modulators do not"],"prefix":"10.1186","volume":"12","author":[{"given":"Christian B.","family":"Lessard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgardo","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas B.","family":"Ladd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Minter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A.","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucio","family":"Miele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd E.","family":"Golde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9748-4392","authenticated-orcid":false,"given":"Yong","family":"Ran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,19]]},"reference":[{"key":"622_CR1","doi-asserted-by":"crossref","unstructured":"Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L. gamma-Secretase inhibitors and modulators. Biochim Biophys Acta 2013;1828(12):2898\u20132907.","DOI":"10.1016\/j.bbamem.2013.06.005"},{"issue":"2","key":"622_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrneurol.2009.218","volume":"6","author":"B De Strooper","year":"2010","unstructured":"De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010;6(2):99\u2013107.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"622_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3233\/JAD-2011-101065","volume":"25","author":"A Haapasalo","year":"2011","unstructured":"Haapasalo A, Kovacs DM. The many substrates of presenilin\/gamma-secretase. J Alzheimers Dis. 2011;25(1):3\u201328.","journal-title":"J Alzheimers Dis"},{"issue":"6727","key":"622_CR4","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/19083","volume":"398","author":"B De Strooper","year":"1999","unstructured":"De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999;398(6727):518\u201322.","journal-title":"Nature."},{"issue":"43","key":"622_CR5","doi-asserted-by":"publisher","first-page":"40268","DOI":"10.1074\/jbc.M107234200","volume":"276","author":"MT Saxena","year":"2001","unstructured":"Saxena MT, Schroeter EH, Mumm JS, Kopan R. Murine notch homologs (N1-4) undergo presenilin-dependent proteolysis. J Biol Chem. 2001;276(43):40268\u201373.","journal-title":"J Biol Chem"},{"issue":"41","key":"622_CR6","doi-asserted-by":"publisher","first-page":"13042","DOI":"10.1523\/JNEUROSCI.2362-09.2009","volume":"29","author":"M Takami","year":"2009","unstructured":"Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, et al. gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci. 2009;29(41):13042\u201352.","journal-title":"J Neurosci"},{"issue":"6","key":"622_CR7","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1074\/jbc.M113.512921","volume":"289","author":"Y Ran","year":"2014","unstructured":"Ran Y, Cruz PE, Ladd TB, Fauq AH, Jung JI, Matthews J, et al. gamma-Secretase processing and effects of gamma-secretase inhibitors and modulators on long Abeta peptides in cells. J Biol Chem. 2014;289(6):3276\u201387.","journal-title":"J Biol Chem"},{"issue":"12","key":"622_CR8","doi-asserted-by":"publisher","first-page":"7890","DOI":"10.1074\/jbc.M513250200","volume":"281","author":"M Okochi","year":"2006","unstructured":"Okochi M, Fukumori A, Jiang J, Itoh N, Kimura R, Steiner H, et al. Secretion of the Notch-1 Abeta-like peptide during Notch signaling. J Biol Chem. 2006;281(12):7890\u20138.","journal-title":"J Biol Chem"},{"issue":"42","key":"622_CR9","doi-asserted-by":"publisher","first-page":"9023","DOI":"10.1021\/bi2007146","volume":"50","author":"O Quintero-Monzon","year":"2011","unstructured":"Quintero-Monzon O, Martin MM, Fernandez MA, Cappello CA, Krzysiak AJ, Osenkowski P, et al. Dissociation between the processivity and total activity of gamma-secretase: implications for the mechanism of Alzheimer\u2019s disease-causing presenilin mutations. Biochemistry. 2011;50(42):9023\u201335.","journal-title":"Biochemistry."},{"issue":"1","key":"622_CR10","doi-asserted-by":"publisher","first-page":"a006304","DOI":"10.1101\/cshperspect.a006304","volume":"2","author":"B De Strooper","year":"2012","unstructured":"De Strooper B, Iwatsubo T, Wolfe MS. Presenilins and gamma-secretase: structure, function, and role in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(1):a006304.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"50","key":"622_CR11","doi-asserted-by":"publisher","first-page":"21236","DOI":"10.1073\/pnas.1016284108","volume":"107","author":"CB Lessard","year":"2010","unstructured":"Lessard CB, Wagner SL, Koo EH. And four equals one: presenilin takes the gamma-secretase role by itself. Proc Natl Acad Sci U S A. 2010;107(50):21236\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"622_CR12","doi-asserted-by":"publisher","first-page":"6382","DOI":"10.1073\/pnas.1037392100","volume":"100","author":"WT Kimberly","year":"2003","unstructured":"Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci U S A. 2003;100(11):6382\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"40","key":"622_CR13","doi-asserted-by":"publisher","first-page":"41340","DOI":"10.1074\/jbc.M405768200","volume":"279","author":"K Shirotani","year":"2004","unstructured":"Shirotani K, Edbauer D, Prokop S, Haass C, Steiner H. Identification of distinct gamma-secretase complexes with different APH-1 variants. J Biol Chem. 2004;279(40):41340\u20135.","journal-title":"J Biol Chem"},{"issue":"10","key":"622_CR14","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1038\/emboj.2012.79","volume":"31","author":"L Chavez-Gutierrez","year":"2012","unstructured":"Chavez-Gutierrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, et al. The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. EMBO J. 2012;31(10):2261\u201374.","journal-title":"EMBO J"},{"key":"622_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13024-015-0021-z","volume":"10","author":"JI Jung","year":"2015","unstructured":"Jung JI, Price AR, Ladd TB, Ran Y, Park HJ, Ceballos-Diaz C, et al. Cholestenoic acid, an endogenous cholesterol metabolite, is a potent gamma-secretase modulator. Mol Neurodegener. 2015;10:29.","journal-title":"Mol Neurodegener"},{"issue":"6860","key":"622_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/35102591","volume":"414","author":"S Weggen","year":"2001","unstructured":"Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001;414(6860):212\u20136.","journal-title":"Nature."},{"issue":"34","key":"622_CR17","doi-asserted-by":"publisher","first-page":"31831","DOI":"10.1074\/jbc.M303592200","volume":"278","author":"S Weggen","year":"2003","unstructured":"Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem. 2003;278(34):31831\u20137.","journal-title":"J Biol Chem"},{"issue":"3","key":"622_CR18","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1172\/JCI18162","volume":"112","author":"JL Eriksen","year":"2003","unstructured":"Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003;112(3):440\u20139.","journal-title":"J Clin Invest"},{"issue":"5","key":"622_CR19","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nm1235","volume":"11","author":"T Kukar","year":"2005","unstructured":"Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med. 2005;11(5):545\u201350.","journal-title":"Nat Med"},{"issue":"4","key":"622_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N Engl J Med. 2013;369(4):341\u201350.","journal-title":"N Engl J Med"},{"issue":"2","key":"622_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/ana.22365","volume":"69","author":"NF Schor","year":"2011","unstructured":"Schor NF. What the halted phase III gamma-secretase inhibitor trial may (or may not) be telling us. Ann Neurol. 2011;69(2):237\u20139.","journal-title":"Ann Neurol"},{"issue":"5","key":"622_CR22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nrd4252","volume":"13","author":"ER Andersson","year":"2014","unstructured":"Andersson ER, Lendahl U. Therapeutic modulation of Notch signalling--are we there yet? Nat Rev Drug Discov. 2014;13(5):357\u201378.","journal-title":"Nat Rev Drug Discov"},{"key":"622_CR23","first-page":"1249","volume":"6","author":"I Espinoza","year":"2013","unstructured":"Espinoza I, Pochampally R, Xing F, Watabe K, Miele L. Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition. Onco Targets Ther. 2013;6:1249\u201359.","journal-title":"Onco Targets Ther"},{"issue":"7","key":"622_CR24","doi-asserted-by":"publisher","first-page":"950","DOI":"10.15252\/emmm.201607265","volume":"9","author":"Y Ran","year":"2017","unstructured":"Ran Y, Hossain F, Pannuti A, Lessard CB, Ladd GZ, Jung JI, et al. gamma-Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct. EMBO Mol Med. 2017;9(7):950\u201366.","journal-title":"EMBO Mol Med"},{"issue":"29","key":"622_CR25","doi-asserted-by":"publisher","first-page":"11276","DOI":"10.1074\/jbc.RA119.008041","volume":"294","author":"CB Lessard","year":"2019","unstructured":"Lessard CB, Rodriguez E, Ladd TB, Minter LM, Osborne BA, Miele L, et al. Individual and combined presenilin 1 and 2 knockouts reveal that both have highly overlapping functions in HEK293T cells. J Biol Chem. 2019;294(29):11276\u201385.","journal-title":"J Biol Chem"},{"issue":"494","key":"622_CR26","doi-asserted-by":"publisher","first-page":"eaau6246","DOI":"10.1126\/scitranslmed.aau6246","volume":"11","author":"Roger A. Habets","year":"2019","unstructured":"Habets RA, de Bock CE, Serneels L, Lodewijckx I, Verbeke D, Nittner D, et al. Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition. Sci Transl Med. 2019;11(494):eaau6246.","journal-title":"Science Translational Medicine"},{"issue":"39","key":"622_CR27","doi-asserted-by":"publisher","first-page":"32640","DOI":"10.1074\/jbc.M112.376541","volume":"287","author":"J Wanngren","year":"2012","unstructured":"Wanngren J, Ottervald J, Parpal S, Portelius E, Stromberg K, Borgegard T, et al. Second generation gamma-secretase modulators exhibit different modulation of Notch beta and Abeta production. J Biol Chem. 2012;287(39):32640\u201350.","journal-title":"J Biol Chem"},{"issue":"10","key":"622_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111553","volume":"9","author":"JI Jung","year":"2014","unstructured":"Jung JI, Premraj S, Cruz PE, Ladd TB, Kwak Y, Koo EH, et al. Independent relationship between amyloid precursor protein (APP) dimerization and gamma-secretase processivity. PLoS One. 2014;9(10):e111553.","journal-title":"PLoS One"},{"issue":"12","key":"622_CR29","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1021\/bi401521t","volume":"53","author":"JI Jung","year":"2014","unstructured":"Jung JI, Ran Y, Cruz PE, Rosario AM, Ladd TB, Kukar TL, et al. Complex relationships between substrate sequence and sensitivity to alterations in gamma-secretase processivity induced by gamma-secretase modulators. Biochemistry. 2014;53(12):1947\u201357.","journal-title":"Biochemistry."},{"issue":"12","key":"622_CR30","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.15252\/embj.201488795","volume":"34","author":"HJ Park","year":"2015","unstructured":"Park HJ, Ran Y, Jung JI, Holmes O, Price AR, Smithson L, et al. The stress response neuropeptide CRF increases amyloid-beta production by regulating gamma-secretase activity. EMBO J. 2015;34(12):1674\u201386.","journal-title":"EMBO J"},{"issue":"17","key":"622_CR31","doi-asserted-by":"publisher","first-page":"11914","DOI":"10.1074\/jbc.274.17.11914","volume":"274","author":"MP Murphy","year":"1999","unstructured":"Murphy MP, Hickman LJ, Eckman CB, Uljon SN, Wang R, Golde TE. gamma-Secretase, evidence for multiple proteolytic activities and influence of membrane positioning of substrate on generation of amyloid beta peptides of varying length. J Biol Chem. 1999;274(17):11914\u201323.","journal-title":"J Biol Chem"},{"issue":"43","key":"622_CR32","doi-asserted-by":"publisher","first-page":"37181","DOI":"10.1074\/jbc.C111.276972","volume":"286","author":"A Ebke","year":"2011","unstructured":"Ebke A, Luebbers T, Fukumori A, Shirotani K, Haass C, Baumann K, et al. Novel gamma-secretase enzyme modulators directly target presenilin protein. J Biol Chem. 2011;286(43):37181\u20136.","journal-title":"J Biol Chem"},{"issue":"3","key":"622_CR33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.cell.2017.07.004","volume":"170","author":"M Szaruga","year":"2017","unstructured":"Szaruga M, Munteanu B, Lismont S, Veugelen S, Horre K, Mercken M, et al. Alzheimer\u2019s-causing mutations shift Abeta length by destabilizing gamma-secretase-Abetan interactions. Cell. 2017;170(3):443\u201356 e14.","journal-title":"Cell."},{"issue":"1","key":"622_CR34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.cell.2016.05.020","volume":"166","author":"R Sannerud","year":"2016","unstructured":"Sannerud R, Esselens C, Ejsmont P, Mattera R, Rochin L, Tharkeshwar AK, et al. Restricted location of PSEN2\/gamma-secretase determines substrate specificity and generates an intracellular Abeta pool. Cell. 2016;166(1):193\u2013208.","journal-title":"Cell."},{"issue":"3","key":"622_CR35","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1074\/jbc.M113.498246","volume":"289","author":"F Olsson","year":"2014","unstructured":"Olsson F, Schmidt S, Althoff V, Munter LM, Jin S, Rosqvist S, et al. Characterization of intermediate steps in amyloid beta (Abeta) production under near-native conditions. J Biol Chem. 2014;289(3):1540\u201350.","journal-title":"J Biol Chem"},{"issue":"4","key":"622_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/alzrt269","volume":"6","author":"JL Cummings","year":"2014","unstructured":"Cummings JL, Morstorf T, Zhong K. Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6(4):37.","journal-title":"Alzheimers Res Ther"},{"issue":"6420","key":"622_CR37","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1126\/science.aau0437","volume":"362","author":"TE Golde","year":"2018","unstructured":"Golde TE, DeKosky ST, Galasko D. Alzheimer\u2019s disease: the right drug, the right time. Science. 2018;362(6420):1250\u20131.","journal-title":"Science."},{"issue":"2","key":"622_CR38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.neuron.2011.01.002","volume":"69","author":"TE Golde","year":"2011","unstructured":"Golde TE, Schneider LS, Koo EH. Anti-abeta therapeutics in Alzheimer\u2019s disease: the need for a paradigm shift. Neuron. 2011;69(2):203\u201313.","journal-title":"Neuron."},{"key":"622_CR39","unstructured":"alzforum. https:\/\/www.alzforum.org\/news\/research-news\/end-bace-inhibitors-elenbecestat-trials-halted-amid-safety-concerns, Accessed 1 Mar 2020."},{"issue":"1","key":"622_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1172\/JCI200317527","volume":"111","author":"TE Golde","year":"2003","unstructured":"Golde TE. Alzheimer disease therapy: can the amyloid cascade be halted? J Clin Invest. 2003;111(1):11\u20138.","journal-title":"J Clin Invest"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00622-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-020-00622-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00622-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T23:50:18Z","timestamp":1621381818000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-020-00622-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["622"],"URL":"https:\/\/doi.org\/10.1186\/s13195-020-00622-5","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,19]]},"assertion":[{"value":"30 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}